Scancell eyeing investigational new drug application for SCIB1 in first half Patient enrolment for the SCIB1 Phase 2 checkpoint inhibitor combination study for patients with advanced melanoma is planned to start in the second half of the year [View article] Tuesday 30 January 2018 12:58 Categories: Media Coverage SCIB1 Year - 2018 Previous Post << >> Next Post